P L Toogood

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Inhibition of protein-protein association by small molecules: approaches and progress
    Peter L Toogood
    Department of Medicinal Chemistry, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 45:1543-58. 2002
  2. ncbi Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
    Peter L Toogood
    Medicinal Chemistry, Cancer Pharmacology, and Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2388-406. 2005
  3. ncbi A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model
    Eline Menu
    Vrije Universiteit Brussels, Laarbeeklaan 103, Brussels, Belgium
    Cancer Res 68:5519-23. 2008
  4. ncbi Cyclin-dependent kinase inhibitors for treating cancer
    P L Toogood
    Department of Medicinal Chemistry, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, Michigan 48105, USA
    Med Res Rev 21:487-98. 2001
  5. ncbi Progress toward the development of agents to modulate the cell cycle
    Peter L Toogood
    Pfizer Global Research and Development 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Curr Opin Chem Biol 6:472-8. 2002
  6. ncbi Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
    David W Fry
    Cancer Pharmacology, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    Mol Cancer Ther 3:1427-38. 2004
  7. ncbi Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4
    Scott N VanderWel
    Department of Medicinal Chemistry, and Cancer Pharmacology, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2371-87. 2005
  8. ncbi The kinome is not enough
    Peter L Toogood
    Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, 48105, USA
    Chem Biol 12:1057-8. 2005
  9. ncbi 2-Aminoquinazoline inhibitors of cyclin-dependent kinases
    Yadagiri Bathini
    NAEJA Pharmaceutical Inc, 2, 4290-91A Street, Edmonton, Alberta, Canada T65VE
    Bioorg Med Chem Lett 15:3881-5. 2005
  10. ncbi A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
    Linda B Baughn
    Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Res 66:7661-7. 2006

Collaborators

Detail Information

Publications10

  1. ncbi Inhibition of protein-protein association by small molecules: approaches and progress
    Peter L Toogood
    Department of Medicinal Chemistry, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 45:1543-58. 2002
  2. ncbi Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
    Peter L Toogood
    Medicinal Chemistry, Cancer Pharmacology, and Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2388-406. 2005
    ..On the basis of its selectivity profile and pharmacokinetic profile, compound 43 (PD 0332991) was identified as a drug candidate for the treatment of cancer...
  3. ncbi A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model
    Eline Menu
    Vrije Universiteit Brussels, Laarbeeklaan 103, Brussels, Belgium
    Cancer Res 68:5519-23. 2008
    ....
  4. ncbi Cyclin-dependent kinase inhibitors for treating cancer
    P L Toogood
    Department of Medicinal Chemistry, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, Michigan 48105, USA
    Med Res Rev 21:487-98. 2001
    ..a matched Rb(-) cell line and to produce a distinct G(1) block consistent with cyclin D/Cdk4 inhibition in cells...
  5. ncbi Progress toward the development of agents to modulate the cell cycle
    Peter L Toogood
    Pfizer Global Research and Development 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Curr Opin Chem Biol 6:472-8. 2002
    ..Flavopiridol and UCN-01 are continuing in clinical trials, and newer more selective Cdk inhibitors are now entering clinical evaluation...
  6. ncbi Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
    David W Fry
    Cancer Pharmacology, Pfizer Global Research and Development, Ann Arbor, Michigan 48105, USA
    Mol Cancer Ther 3:1427-38. 2004
    ..The results indicate that inhibition of Cdk4/6 alone is sufficient to cause tumor regression and a net reduction in tumor burden in some tumors...
  7. ncbi Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4
    Scott N VanderWel
    Department of Medicinal Chemistry, and Cancer Pharmacology, Pfizer Global Research and Development, Michigan Laboratories, 2800 Plymouth Road, Ann Arbor, Michigan 48105, USA
    J Med Chem 48:2371-87. 2005
    ..The most selective Cdk4 inhibitors were evaluated for antitumor activity against MDA-MB-435 human breast carcinoma xenografts in mice...
  8. ncbi The kinome is not enough
    Peter L Toogood
    Pfizer Global Research and Development, Michigan Laboratories, Ann Arbor, 48105, USA
    Chem Biol 12:1057-8. 2005
    ..Caligiuri and coworkers describe how yeast three-hybrid screening identified kinases that might mediate an intriguing tumor cell-specific antiproliferative effect...
  9. ncbi 2-Aminoquinazoline inhibitors of cyclin-dependent kinases
    Yadagiri Bathini
    NAEJA Pharmaceutical Inc, 2, 4290-91A Street, Edmonton, Alberta, Canada T65VE
    Bioorg Med Chem Lett 15:3881-5. 2005
    ..Compounds that inhibit Cdk4 selectively are targeted for treating cancer. Appropriate substitution of 2-aminoquinazolines is demonstrated to produce high levels of selectivity for Cdk4 versus closely related serine-threonine kinases...
  10. ncbi A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
    Linda B Baughn
    Department of Pathology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Cancer Res 66:7661-7. 2006
    ..PD 0332991, therefore, represents the first promising and specific inhibitor for therapeutic targeting of Cdk4/6 in multiple myeloma and possibly other B-cell cancers...